【开放获取】环孢素治疗免疫相关性皮肤病专家建议

doi:10.35541/cjd.20210434

Abstract

Abstract: 【Abstract】 Cyclosporine, a kind of calcineurin inhibitor, is a potent non-cytotoxic immunosuppressant. It mainly acts on T lymphocytes and exerts an immunosuppressive effect by inhibiting T lymphocyte proliferation and cytokine transcription. Cyclosporine is commonly used in the treatment of psoriasis and atopic dermatitis in dermatology, and has also been reported for the treatment of systemic lupus erythematosus, dermatomyositis, vasculitis and other diseases. Based on Chinese and international literature （mainly including randomized controlled clinical trials, expert consensus or proposals）on cyclosporine in the treatment of immune-related skin diseases, relevant Chinese experts developed a proposal on cyclosporine in the treatment of immune-related skin diseases after repeated discussions.

Key words: Cyclosporine, Autoimmune diseases, Psoriasis, Lupus erythematosus, systemic, Dermatomyositis, Scleroderma, localized, Skin diseases, vesiculobullous

Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal[J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.doi:10.35541/cjd.20210434

References ［72］

［1］	Berth⁃Jones J, Exton LS, Ladoyanni E, et al. British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018［J］. Br J Dermatol, 2019,180（6）:1312⁃1338. doi: 10.1111/bjd.17587.
［2］	中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南［J］. 中华内科杂志, 2020,59（3）:172⁃185. doi: 10.3760/cma.j.issn.0578⁃1426.2020.03.002.
［3］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018完整版）［J］. 中华皮肤科杂志, 2019,52（10）:667⁃710. doi: 10.35541/cjd.20190847.
［4］	Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin⁃A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia［J］. Clin Rheumatol, 2011,30（8）:1021⁃1028. doi: 10.1007/s10067⁃011⁃1713⁃6.
［5］	Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part Ⅱ［J］. J Am Acad Dermatol, 2010,63（6）:949⁃974. doi: 10.1016/j.jaad.2010.02.062.
［6］	Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents［J］. J Am Acad Dermatol, 2014,71（2）:327⁃349. doi: 10.1016/j.jaad.2014.03.030.
［7］	Wissing KM, Abramowicz D, Weekers L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation［J］. Am J Transplant, 2018,18（7）:1726⁃1734. doi: 10.1111/ajt.14665.
［8］	Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies［J］. J Am Acad Dermatol, 2020,82（6）:1445⁃1486. doi: 10.1016/j.jaad.2020.02.044.
［9］	Jacobs A, Rosumeck S, Nast A. Systematic review on the maintenance of response during systemic antipsoriatic therapy［J］. Br J Dermatol, 2015,173（4）:910⁃921. doi: 10.1111/bjd. 14077.
［10］	Shi L, Lian N, Liu L, et al. Tapering and discontinuation of systemic medications in psoriasis patients with low disease activity［J］. Dermatol Ther, 2020,33（4）:e13599. doi: 10.1111/dth.13599.
［11］	Vena GA, Galluccio A, Pezza M, et al. Combined treatment with low⁃dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate⁃to⁃severe plaque psoriasis: a randomized controlled open⁃label study［J］. J Dermatolog Treat, 2012,23（4）:255⁃260. doi: 10.3109/09546634.2011.565017.
［12］	Griffiths CE, Powles AV, McFadden J, et al. Long⁃term cyclosporin for psoriasis［J］. Br J Dermatol, 1989,120（2）:253⁃260. doi: 10.1111/j.1365⁃2133.1989.tb07790.x.
［13］	Clark CM, Kirby B, Morris AD, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis［J］. Br J Dermatol, 1999,141（2）:279⁃282. doi: 10.1046/ j.1365⁃2133.1999.02976.x.
［14］	Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis［J］. Ann Rheum Dis, 2005,64（6）:859⁃864. doi: 10.1136/ard.2004.024463.
［15］	Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis［J］. Clin Exp Dermatol, 2001,26（6）:480⁃483. doi: 10.1046/j. 1365⁃2230.2001.00870.x.
［16］	Balasubramaniam P, Stevenson O, Berth⁃Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities［J］. Br J Dermatol, 2004,150（4）:741⁃746. doi: 10.1111/j.0007⁃0963.2004.05739.x.
［17］	Strober BE, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities［J］. J Drugs Dermatol, 2004,3（3）:270⁃272.
［18］	Yamauchi PS, Lowe NJ. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis［J］. J Am Acad Dermatol, 2006,54（3 Suppl 2）:S135⁃S138. doi: 10. 1016/j.jaad.2005.11.1043.
［19］	Babino G, Giunta A, Ruzzetti M, et al. Combination therapy with etanercept in psoriasis: retrospective analysis of efficacy and safety outcomes from real⁃life practice［J］. J Int Med Res, 2016,44（1 suppl）:100⁃105. doi: 10.1177/0300060515593260.
［20］	Karanikolas GN, Koukli EM, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12⁃month nonrandomized unblinded clinical trial［J］. J Rheumatol, 2011,38（11）:2466⁃2474. doi: 10.3899/jrheum.110242.
［21］	Kelly Ⅲ JB, Foley P, Strober BE. Current and future oral systemic therapies for psoriasis［J］. Dermatol Clin, 2015,33（1）:91⁃109. doi: 10.1016/j.det.2014.09.008.
［22］	中华医学会皮肤性病学分会免疫学组特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000.
［23］	Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate⁃to⁃severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies［J］. J Allergy Clin Immunol Pract, 2017,5（6）:1519⁃1531. doi: 10.1016/j.jaip.2017.08.005.
［24］	Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part Ⅱ［J］. J Eur Acad Dermatol Venereol, 2018,32（6）:850⁃878. doi: 10.1111/jdv.14888.
［25］	Prezzano JC, Beck LA. Long⁃term treatment of atopic dermatitis［J］. Dermatol Clin, 2017,35（3）:335⁃349. doi: 10.1016/j.det.2017. 02.007.
［26］	Damiani G, Calzavara⁃Pinton P, Stingeni L, et al. Italian guidelines for therapy of atopic dermatitis⁃adapted from consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis）［J］. Dermatol Ther, 2019,32（6）:e13121. doi: 10.1111/dth.13121.
［27］	Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018［J］. J Dermatol, 2019,46（12）:1053⁃1101. doi: 10.1111/1346⁃8138.15090.
［28］	Rajagopalan M, De A, Godse K, et al. Guidelines on management of atopic dermatitis in india: an evidence⁃based review and an expert consensus［J］. Indian J Dermatol, 2019,64（3）:166⁃181. doi: 10.4103/ijd.IJD_683_18.
［29］	Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association⁃European Dialysis and Transplant Association （EULAR/ERA⁃EDTA） recommendations for the management of lupus nephritis［J］. Ann Rheum Dis, 2020,79（6）:713⁃723. doi: 10.1136/annrheumdis⁃2020⁃216924.
［30］	Caccavo D, Laganà B, Mitterhofer AP, et al. Long⁃term treatment of systemic lupus erythematosus with cyclosporin A［J］. Arthritis Rheum, 1997,40（1）:27⁃35. doi: 10.1002/art.17804 00106.
［31］	Germano V, Picchianti Diamanti A, Ferlito C, et al. Cyclosporine A in the long⁃term management of systemic lupus erythematosus［J］. J Biol Regul Homeost Agents, 2011,25（3）:397⁃403.
［32］	Griffiths B, Emery P, Ryan V, et al. The BILAG multi⁃centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE［J］. Rheumatology （Oxford）, 2010,49（4）:723⁃732. doi: 10.1093/rheumatology/kep396.
［33］	Gordon C, Amissah⁃Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults［J］. Rheumatology （Oxford）, 2018,57（1）:e1⁃e45. doi: 10.1093/rheumatology/kex286.
［34］	Ogawa H, Kameda H, Nagasawa H, et al. Prospective study of low⁃dose cyclosporine A in patients with refractory lupus nephritis［J］. Mod Rheumatol, 2007,17（2）:92⁃97. doi: 10.1007/s10165⁃006⁃0545⁃8.
［35］	Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years［J］. Clin J Am Soc Nephrol, 2006,1（5）:925⁃932. doi: 10.2215/CJN.02271205.
［36］	中华医学会皮肤性病学分会红斑狼疮研究中心. 皮肤型红斑狼疮诊疗指南（2019版）［J］. 中华皮肤科杂志, 2019,52（3）:149⁃155. doi: 10.3760/cma.j.issn.0412⁃4030.2019.03.001.
［37］	Nagai K, Takeuchi T, Kotani T, et al. Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis［J］. Mod Rheumatol, 2011,21（1）:32⁃36. doi: 10.1007/s10165⁃010⁃0342⁃2.
［38］	Vencovský J, Jarosová K, Machácek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis［J］. Scand J Rheumatol, 2000,29（2）:95⁃102. doi: 10.1080/030097400750001897.
［39］	Ibrahim F, Choy E, Gordon P, et al. Second⁃line agents in myositis: 1⁃year factorial trial of additional immunosuppression in patients who have partially responded to steroids［J］. Rheumatology （Oxford）, 2015,54（6）:1050⁃1055. doi: 10.1093/rheumatology/keu442.
［40］	Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new⁃onset juvenile dermatomyositis: a randomised trial［J］. Lancet, 2016,387（10019）:671⁃678. doi: 10.1016/S0140⁃6736（15）01021⁃1.
［41］	Bellutti Enders F, Bader⁃Meunier B, Baildam E, et al. Consensus⁃based recommendations for the management of juvenile dermatomyositis［J］. Ann Rheum Dis, 2017,76（2）:329⁃340. doi: 10.1136/annrheumdis⁃2016⁃209247.
［42］	Huber AM, Kim S, Reed AM, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash［J］. J Rheumatol, 2017,44（1）:110⁃116. doi: 10.3899/jrheum.160688.
［43］	Lohi J, Kähäri VM, Keski⁃Oja J. Cyclosporin A enhances cytokine and phorbol ester⁃induced fibroblast collagenase expression［J］. J Invest Dermatol, 1994,102（6）:938⁃944. doi: 10.1111/1523⁃1747.ep12384105.
［44］	Roch B, Wollina U, Schroeder HE. Long⁃term cyclosporin A in systemic sclerosis［J］. J Eur Acad Dermatol Venereol, 2004,18（2）:235⁃236. doi: 10.1111/j.1468⁃3083.2004.00717.x.
［45］	Ogawa T, Okiyama N, Takamuki R, et al. Juvenile case of multiple morphea profunda resulting in joint contracture that was successfully treated with cyclosporin A: a case report and review of the published works［J］. J Dermatol, 2019,46（4）:354⁃357. doi: 10.1111/1346⁃8138.14801.
［46］	Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis. Results of a forty⁃eight⁃week open safety study in ten patients［J］. Arthritis Rheum, 1993,36（1）:75⁃83. doi: 10.1002/art.1780360113.
［47］	Bali G, Frühauf J, Wutte N, et al. Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review［J］. Dermatology, 2016,232（4）:503⁃510. doi: 10.1159/000448171.
［48］	Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet′s syndrome［J］. Ann Rheum Dis, 2018,77（6）:808⁃818. doi: 10. 1136/annrheumdis⁃2018⁃213225.
［49］	Chighizola CB, Ong VH, Meroni PL. The use of cyclosporine A in rheumatology: a 2016 comprehensive review［J］. Clin Rev Allergy Immunol, 2017,52（3）:401⁃423. doi: 10.1007/s12016⁃016⁃8582⁃3.
［50］	Koskela M, Jahnukainen T, Endén K, et al. Methylprednisolone or cyclosporine a in the treatment of Henoch⁃Schönlein nephritis: a nationwide study［J］. Pediatr Nephrol, 2019,34（8）:1447⁃1456. doi: 10.1007/s00467⁃019⁃04238⁃2.
［51］	Carlson JA, Cavaliere LF, Grant⁃Kels JM. Cutaneous vasculitis: diagnosis and management［J］. Clin Dermatol, 2006,24（5）:414⁃429. doi: 10.1016/j.clindermatol.2006.07.007.
［52］	Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus［J］. Arch Dermatol, 2000,136（7）:868⁃872. doi: 10. 1001/archderm.136.7.868.
［53］	Olszewska M, Kolacinska⁃Strasz Z, Sulej J, et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine （ciclosporin） as adjuvant drugs in pemphigus vulgaris［J］. Am J Clin Dermatol, 2007,8（2）:85⁃92. doi: 10.2165/00128071⁃2007 08020⁃00004.
［54］	Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists′ guidelines for the management of pemphigus vulgaris 2017［J］. Br J Dermatol, 2017,177（5）:1170⁃1201. doi: 10.1111/bjd.15930.
［55］	Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology［J］. Br J Dermatol, 2015,172（4）:867⁃877. doi: 10. 1111/bjd.13717.
［56］	Intong LR, Murrell DF. Management of epidermolysis bullosa acquisita. Dermatol Clin, 2011,29（4）:643⁃647. doi: 10.1016/j.det.2011.06.020.
［57］	Santi CG, Gripp AC, Roselino AM, et al. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita ⁃ Brazilian Society of Dermatology［J］. An Bras Dermatol, 2019,94（2 Suppl 1）:33⁃47. doi: 10.1590/abd1806⁃4841.2019940207.
［58］	Hong JR, Lee YW, Choe YB, et al. Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real⁃world practice［J］. Dermatol Ther, 2019,32（3）:e12875. doi: 10.1111/dth.12875.
［59］	Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part Ⅱ［J］. J Am Acad Dermatol, 2010,63（6）:949⁃972; quiz 973⁃974. doi: 10.1016/j.jaad.2010.02.062.
［60］	Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study［J］. J Invest Dermatol, 2003,120（2）:211⁃216. doi: 10.1046/j. 1523⁃1747.2003.12040.x.
［61］	Zachariae H, Heickendorff L, Bjerring P. Plasma endothelin in psoriasis: possible relations to therapy and toxicity［J］. Acta Derm Venereol, 1996,76（6）:442⁃443. doi: 10.2340/0001555576 442443.
［62］	Hernández⁃Martín A, Noguera⁃Morel L, Bernardino⁃Cuesta B, et al. Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:837⁃842. doi: 10.1111/ jdv.14066.
［63］	Ogawa H, Kameda H, Amano K, et al. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice［J］. Lupus, 2010,19（2）:162⁃169. doi: 10.1177/0961203309350320.
［64］	Allen BR. Use of cyclosporin for psoriasis in HIV⁃positive patient［J］. Lancet, 1992,339（8794）:686. doi: 10.1016/0140⁃6736（92）90852⁃t.
［65］	Tourne L, Durez P, Van Vooren JP, et al. Alleviation of HIV⁃associated psoriasis and psoriatic arthritis with cyclosporine［J］. J Am Acad Dermatol, 1997,37（3 Pt 1）:501⁃502. doi: 10.1016/s0190⁃9622（97）70160⁃9.
［66］	中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南（2010年版）［J］. 中华肝脏病杂志, 2011,19（1）:13⁃24. doi: 10.3760/cma.j.issn.1007⁃3418.2011.01.007.
［67］	Galeazzi M, Bellisai F, Manganelli S, et al. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients［J］. Autoimmun Rev, 2006,5（7）:493⁃498. doi: 10.1016/j.autrev. 2006.01.002.
［68］	亚太医学生物免疫学会儿童过敏免疫风湿病分会, 《中国实用儿科杂志》编辑委员会. 儿童免疫相关性疾病临床实用热点问题专家建议系列之三——环孢素在中国儿童免疫相关疾病中的应用建议［J］. 中国实用儿科杂志, 2020,35（6）:417⁃423,434. doi: 10.19538/j.ek2020060601.
［69］	Feutren G, Friend D, Timonen P, et al. Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis［J］. Br J Dermatol, 1990,122 Suppl 36:85⁃93. doi: 10.1111/j.1365⁃2133.1990.tb02886.x.
［70］	Bar Oz B, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta⁃analysis［J］. Transplantation, 2001,71（8）:1051⁃1055. doi: 10.1097/00007890⁃ 200104270⁃00006.
［71］	Unver Dogan N, Uysal II, Fazliogullari Z, et al. Investigation of developmental toxicity and teratogenicity of cyclosporine A, tacrolimus and their combinations with prednisolone［J］. Regul Toxicol Pharmacol, 2016,77:213⁃222. doi: 10.1016/j.yrtph.2016. 03.010.
［72］	Ozawa A, Sugai J, Ohkido M, et al. Cyclosporin in psoriasis: continuous monotherapy versus intermittent long⁃term therapy［J］. Eur J Dermatol, 1999,9（3）:218⁃223.

[1]	WANG Chang-yuan, ZHANG Ping-zhao, ZHANG Fu-ren, LIU Jie, TIAN Hong-qing, YU Long. ECM1 Gene Mutations in a Family with Lipoid Proteinosis[J]. Chinese Journal of Dermatology, 2005, 38(11): 659 -661 .
[2]	LIN Neng-xing, ZHANG Li-xia, HUANG Chang-zheng, CHEN Hong-xiang, TU Ya-ting. The Mutation of IR Gene in the mtr System and Multiple Antibiotic Resistance of Neisseria gonorrhoeae[J]. Chinese Journal of Dermatology, 2005, 38(12): 719 -721 .
[3]	WENG Yan, LIU Jin-hong, YU Qiao-yi, MA Ping, YANG Yi, LIAO Song-lin. Fibromucinous Primary Cutaneous T-Cell Lymphoma Rich in Blood Vessels: A Case Report[J]. Chinese Journal of Dermatology, 2005, 38(12): 729 -731 .
[4]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 750 .
[5]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 774 .
[6]	李靖华, 周晓鸿. [J]. Chinese Journal of Dermatology, 2005, 38(12): 775 .
[7]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 777 -778 .
[8]	ZHANG Ru-zhi, ZHU Wen-yuan, XIA Ming-yu, WANG Da-guang, MA Hui-jun. Ultrastructural Characteristics of Amelanotic Melanocytes from Human Hair Follicles[J]. Chinese Journal of Dermatology, 2005, 38(11): 671 -673 .
[9]	. [J]. Chinese Journal of Dermatology, 2005, 38(11): 692 -693 .
[10]	夏修蛟, 陶茂灿, 郑俊惠, 金海生, 周谓珩, 许爱娥. [J]. Chinese Journal of Dermatology, 2005, 38(11): 695 .

[1]	Shan Ying, Zuo Yagang. Correlation between autoimmune bullous diseases and psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(5): 452-455.
[2]	Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275.
[3]	Lyu Ling, Lyu Xiaoyan. Dermatomyositis with malignancy: an update [J]. Chinese Journal of Dermatology, 2022, 55(3): 276-279.
[4]	Wang Zhaoyang, Chen Anwei, Xiang Xin, Luo Xiaoyan, Xu Zigang, Wang Hua, Ma Lin. An investigation into the current situation of pediatric psoriasis based on the information systems from two children′s hospitals [J]. Chinese Journal of Dermatology, 2022, 55(3): 246-250.
[5]	Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195.
[6]	Wang Yue, Yan Yulin. Analysis of adverse drug reactions and reasons for drug discontinuation during acitretin therapy in 171 patients with psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(3): 242-245.
[7]	Li Yan, Li Ming, Xu Wei, Li Linfeng. Efficacy of fluticasone propionate cream alone or in combination with calcipotriol ointment in the treatment of mild to moderate plaque psoriasis: a randomized self-controlled study [J]. Chinese Journal of Dermatology, 2022, 55(3): 260-263.
[8]	Zheng Jiayuan, Yu Bingqian, Chen Xianxia, Luo Zhicheng. Characteristics of pruritus in adult patients with psoriasis vulgaris and its effect on quality of life [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210153-e20210153.
[9]	Zhang Tingting, Zhu Fengyi, Yang Mei, Zhang Ping, Xia Ping, Zhou Xiaoyong. Clinical efficacy and safety of secukinumab in the treatment of 7 cases of erythrodermic psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210644-e20210644.
[10]	Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity [J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184.
[11]	Huang Yanzhou, Zheng Min. Antiviral immunity in psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210254-e20210254.
[12]	Zhao Ying, Wang Juanjuan, Ji Jiang, Su Wenxing, Wei Yuqian, Leng Hong, Ding Yujie, Shi Xin. Interleukin-17A-mediated psoriasis and cardiovascular comorbidities [J]. Chinese Journal of Dermatology, 2022, 55(1): 76-79.
[13]	Gao Rong, Zhang Lan, Li Zhengxiao. Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis [J]. Chinese Journal of Dermatology, 2022, 55(1): 72-75.
[14]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210420-e20210420.
[15]	Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(1): 20201086-e20201086.

Cyclosporine in the treatment of immune-related skin diseases: an expert proposal

PDF

Knowledge

Abstract

Cite this article

share this article

References ［72］

Related Articles 15

Metrics

Comments

Recommended 10